Third Rock Ventures

Tango Therapeutics is leveraging the principle of synthetic lethality to develop genetically targeted therapies for specific tumors, focusing on genetically defined subsets of can…

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing breakthrough precision medicines for common diseases, particularly chronic kidney disease, le…

Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of precision small molecule medicines for central nervous system (CNS)…

Septerna is a biotechnology company focused on pioneering GPCR drug discovery through its proprietary Native Complex Platform™, aiming to develop oral small molecule therapies tar…

Details are not available yet. The company remains listed.

Sage Therapeutics is an award-winning biopharmaceutical company with over 30 years of experience in developing and commercializing products that treat central nervous system (CNS)…

Blueprint Medicines is focused on developing innovative therapies for patients with mast cell disorders and solid tumors, utilizing a proven drug discovery platform and robust cli…

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health disorders. The company’s…

Azalea Therapeutics is enabling precision genome engineering directly inside the body, with an initial focus on creating cancer immunotherapies in vivo. The company uses precision…

Insitro is a drug discovery company that leverages machine learning and large-scale data to develop new medicines more efficiently. They focus on understanding complex biological…

Flare Therapeutics is focused on developing small molecule medicines that target transcription factors to treat diseases, particularly in precision oncology. Their pipeline includ…

Candid Therapeutics is a biotech company focused on developing treatments for fungal infections.

Marea Therapeutics is focused on developing next-generation medicines for cardioendocrine diseases by leveraging large-scale human genetic data and advancements in biology.

Advancing novel antidepressants and anxiolytics based on clinically validated mechanisms powered by our Glyph™ platform.

Agios Pharmaceuticals is focused on discovering and developing innovative medicines for patients with rare diseases, particularly those related to metabolic disorders.

Editas Medicine is a pioneering gene editing company focused on developing transformative medicines using CRISPR technology to treat serious diseases.

Fulcrum Therapeutics focuses on developing small molecules to improve the lives of patients with genetically defined rare diseases, particularly in areas of high unmet medical nee…

Element Science is a San Francisco-based medical device and digital health company focused on developing solutions to address the needs of high-risk cardiovascular patients, inclu…

Terremoto Biosciences is a clinical-stage company breaking new ground in the targeted therapy landscape in oncology and genetic disease, focusing on developing groundbreaking, bes…

ARTBIO is redefining cancer care by developing a new class of alpha radioligand therapies (ART) and building the ecosystem that maximizes their potential.

Merida Biosciences is focused on developing precision therapies for autoimmune-driven diseases, targeting the pathogenic drivers of antibody-driven diseases with high specificity.

Corvia Medical is focused on transforming the standard of care for heart failure treatment with its innovative Corvia Atrial Shunt System, aimed at improving quality of life for p…